Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch maintains a Sell rating on Integra Lifesciences and lowers the price target from $23 to $20.
August 22, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup analyst Joanne Wuensch maintains a Sell rating on Integra Lifesciences and lowers the price target from $23 to $20.
The Sell rating and reduced price target from a major financial institution like Citigroup is likely to negatively impact investor sentiment and could lead to a short-term decline in IART's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100